Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Remsima infliximab Crohn’s disease Active
Hemgenix etranacogene dezaparvovec Hemophilia B Active
Bimzelx bimekizumab Psoriatic arthritis Active
Bimzelx bimekizumab Ankylosing spondylitis Active
Awiqli insulin icodec Diabetes mellitus, type 2 Active
TBC lebrikizumab atopic dermatitis Active
Opdivo nivolumab Stage IIB or IIC melanoma, adjuvant Active
Epkinly epcoritamab Relapsed or refractory diffuse large B-cell lymphoma Active
Orgovyx relugolix Advanced prostate cancer Active
Repatha evolocumab Primary hyperlipidemia Active